In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease
Liu, Rong ; Abid, Karim ; Pichardo, John ; Pazienza, Valerio ; Ingravallo, Paul ; Kong, Rong ; Agrawal, Sony ; Bogen, Stephane ; Saksena, Anil ; Cheng, Kuo-Chi ; Prongay, Andrew ; Njoroge, F. George ; Baroudy, Bahige M. ; Negro, Francesco
In: Journal of Antimicrobial Chemotherapy, 2007, vol. 59, no. 1, p. 51-58
Ajouter à la liste personnelle- Summary
- Background: Current hepatitis C virus (HCV) therapies may cure ∼60% of infections. They are often contraindicated or poorly tolerated, underscoring the need for safer and more effective drugs. A novel, α-ketoamide-derived, substrate-based inhibitor of the HCV serine protease (SCH446211) was developed. Compared with earlier reported inhibitors of similar chemical class, it has a P1′-P2′ extension which provides extended interaction with the protease active site. The aim of this study was to evaluate the in vitro antiviral activity of SCH446211. Methods: Binding constant of SCH446211 to HCV NS3 protease was measured with the chromogenic substrate in vitro cleavage assay. Cell-based activity of SCH446211 was evaluated in replicon cells, which are Huh-7 hepatoma cells stably transfected with a subgenomic HCV RNA as reported previously. After 72 h of incubation with SCH446211, viral transcription and protein expression were measured by real-time RT-PCR (TaqMan), quantitative in situ hybridization, immunoblot and indirect immunofluorescence. Results: The binding constant of SCH446211 to HCV NS3 protease was 3.8 ± 0.4 nM. HCV replication and protein expression were inhibited by SCH446211 in replicon cells as consistently shown by four techniques. In particular, based on quantitative real-time RT-PCR measurements, the IC50 and IC90 of SCH446211 were estimated to be 40 ± 20 and 100 ± 20 nM (n = 17), respectively. Long-term culture of replicon cells with SCH446211 reduced replicon RNA to <0.1 copy per cell. SCH446211 did not show cellular toxicity at concentrations up to 50 μM. Conclusions: SCH446211 is a potent inhibitor of HCV protease in vitro. Its extended interaction with the HCV NS3 protease active site is associated with potent in vitro antiviral activity. This observation is potentially a useful guide for development of future potent inhibitors against HCV NS3 protease